Business Update Positive

2026-11-07 15:25

Current scenario - Consolidated revenues reached ₹79.1 billion, up 29% YoY, with an EBITDA margin of 24% and PAT at ₹9.3 billion. - India-branded formulations grew 19% YoY, driven by strong chronic and super specialty portfolio performance. - US business recorded revenues of ₹33.1 billion, up 21% YoY, supported by steady base business and scaling specialty portfolio. - Consumer wellness business grew 76% YoY to ₹11.2 billion. Management Guidance & Outlook - Maintaining FY27 EBITDA margin guidance at 24% plus. - US commercialization expenses for Saroglitazar are expected to be around $100 million annually. - Expecting single-digit constant currency growth for the US business on a high base of FY26. Capex & Debt - Net debt to EBITDA ratio stood at 0.62x as of September 30, 2026, with net debt decreasing from ₹5,900 crores to ₹5,200 crores. - Focused on debt reduction and comfort with a net debt to EBITDA threshold of up to 1x. Growth Drivers - Expansion of specialty and differentiated portfolios including 505(b)(2) filings, biologics, and transdermal patches. - Upcoming launches and global expansion of biosimilars, along with the expected US commercial launch of Saroglitazar.

Business Update Positive

2026-11-07 15:22

Current scenario - Consolidated revenues for Q2 FY27 stood at ₹79.1 billion, up 29% YoY. - EBITDA for the quarter was ₹18.9 billion with an EBITDA margin of 24%. - Net profit for the quarter stood at ₹9.3 billion. - Net debt to EBITDA ratio stood at 0.62x as of September 30, 2026. Changes in trends - India branded formulations business grew 19% YoY, continuing market outperformance. - Consumer wellness business recorded revenues of ₹11.2 billion, up 76% YoY. - US business revenue reached ₹33.1 billion, up 21% YoY, supported by steady volume expansion and scaling of the specialty business. Management Guidance & Outlook - Reaffirmed guidance of delivering 24%+ EBITDA margin for the full year FY27. - Expected commercial expenses for Saroglitazar in the US to be around $100 million annually. - Planning to double transdermal capacity over the next year to address strong unmet market demand. - Aiming for a 20% patient share for Saroglitazar in the US upon launch, with meaningful revenue contribution targeted by FY29-FY30.

Business Update Positive

2026-11-06 19:11

- Zydus Lifesciences announced positive Phase 2b trial results for saroglitazar in adults with MASH and F2-F3 fibrosis. - Resolution of steatohepatitis without worsening of fibrosis was achieved by 39.1% (4 mg) and 32.4% (2 mg) of patients compared to 13.7% for placebo. - Saroglitazar was generally well tolerated with no significant weight gain or drug-induced liver injury signals.

Business Update Positive

2026-11-06 19:09

- Zydus Lifesciences announced positive Phase 2b clinical trial results for investigational drug saroglitazar in adults with MASH and F2-F3 fibrosis. - Resolution of steatohepatitis without worsening of fibrosis was achieved by 39.1% (4 mg dose) and 32.4% (2 mg dose) of patients compared to 13.7% for placebo. - Saroglitazar was generally well tolerated with no significant weight gain or drug-induced liver injury signal.

Ownership Neutral

2026-11-06 15:14

- Life Insurance Corporation of India (LIC) has disclosed the sale of 2,02,42,068 shares (2.029%) of Zydus Lifesciences Ltd. - The transaction took place through market sale between August 28, 2025, and November 5, 2026. - LIC's shareholding in the company decreased from 5.213% (5,20,01,383 shares) to 3.184% (3,17,59,315 shares).

Business Update Neutral

2026-11-05 19:32

- Zydus Lifesciences Limited is participating in the JM Financial 17th Annual Flagship Conference, 'India Xchange 2026'. - The conference is scheduled to be held in Mumbai on November 18, 2026.

Business Update Neutral

2026-11-05 19:30

Concall Schedule Concall Date: November 17, 2026 Concall Details: Participation in Avendus Spark Investor Conference at Mumbai.

Business Update Neutral

2026-11-05 19:30

Concall Schedule Concall Date: November 18, 2026 Concall Time: Not specified - Zydus Lifesciences Limited is participating in the JM Financial 17th Annual Flagship Conference, 'India Xchange 2026' in Mumbai.

Business Update Neutral

2026-11-05 19:18

Concall Schedule Concall Date: November 17, 2026 Concall Time: Not specified Details: Zydus Lifesciences Limited is participating in the Avendus Spark Investor Conference in Mumbai.

Business Update Neutral

2026-11-04 19:24

- Audio recording of the Investor Call discussing financial results for Q2 / H1 ended September 30, 2026 is made available on the Company's website. - The investor call was conducted on November 4, 2026.

Business Update Neutral

2026-11-04 19:22

- Audio recording of the Investor Call for Q2/H1 FY27 results (ended September 30, 2026) is available on the company website. - Investor Call was conducted on November 4, 2026.

Financials Neutral

2026-11-04 12:43

Q2 FY27 Consolidated Revenue ₹7,910 Cr vs ₹6,123 Cr (▲29.2% YoY) EBITDA ₹1,895 Cr vs ₹2,016 Cr (▼6.0% YoY) PAT ₹926 Cr vs ₹1,261 Cr (▼26.6% YoY) EBITDA Margin 24.0% vs 32.9% (▼890bps)

Financials Neutral

2026-11-04 12:42

Q2 FY27 Consolidated Revenue ₹7,910Cr vs ₹6,123Cr (▲29% YoY) EBITDA ₹1,895Cr vs ₹2,016Cr (▼6% YoY) PAT ₹926Cr vs ₹1,261Cr (▼27% YoY) EBITDA Margin 24% vs 33% (▼900bps)

Business Update Neutral

2026-11-04 12:40

- Q2 FY27 revenue from operations rose 29% YoY to ₹79,096 mn. - EBITDA declined 6.0% YoY to ₹18,945 mn, with EBITDA margin at 24.0%. - Net profit decreased 26.6% YoY to ₹9,255 mn. - Net debt stood at ₹51,998 mn with organic capex of ₹4,655 mn.

Business Update Neutral

2026-11-04 12:38

- Q2 FY27 Revenue from Operations grew 29% YoY to ₹79,096 mn. - EBITDA stood at ₹18,945 mn (-6% YoY) with 24.0% margin; PAT declined 26.6% YoY to ₹9,255 mn. - India and North America formulations grew 18.3% and 20.8% YoY, respectively. - Organic Capex reached ₹4,655 mn; Net Debt stood at ₹51,998 mn.

Routine Neutral

2026-11-04 12:37

New Filing detected. See link for details.

Governance Neutral

2026-11-04 12:33

- Zydus Lifesciences Ltd announced the appointment of M/s. Walker Chandiok & Co LLP as the new statutory auditors. - The appointment is for a first term of 5 consecutive years, commencing from the conclusion of the 32nd AGM (FY 2026-2027) until the 37th AGM (FY 2031-2032), subject to shareholder approval. - The change is due to the completion of the second consecutive 5-year term of the existing statutory auditors, Deloitte Haskins and Sells LLP, in compliance with mandatory auditor rotation under the Companies Act, 2013.

Governance Neutral

2026-11-04 12:32

- Zydus Lifesciences Limited announced the appointment of M/s. Walker Chandiok & Co LLP as the new statutory auditors. - The appointment is due to the mandatory rotation and completion of the second 5-year term of the existing auditors, Deloitte Haskins and Sells LLP, at the conclusion of the 32nd AGM. - The new appointment is for a first term of 5 consecutive years, from the conclusion of the 32nd AGM (FY 2026-2027) until the 37th AGM (FY 2031-2032), subject to member approval.

Financials Neutral

2026-11-04 12:28

Q2 FY27 Standalone Revenue ₹3,482 Cr vs ₹2,871 Cr (▲21% YoY) EBITDA ₹1,054 Cr vs ₹1,152 Cr (▼8% YoY) PAT ₹715 Cr vs ₹1,157 Cr (▼38% YoY) EBITDA Margin 30.3% vs 40.1% (▼980bps)

Financials Neutral

2026-11-04 12:25

Q2 FY27 Consolidated Revenue ₹7,910Cr vs ₹6,123Cr (▲29.2% YoY) EBITDA ₹1,923Cr vs ₹1,987Cr (▼3.2% YoY) PAT ₹926Cr vs ₹1,261Cr (▼26.6% YoY) EBITDA Margin 24.3% vs 32.5% (▼813bps)

Financials Neutral

2026-11-04 12:21

Q2 FY27 Consolidated Revenue ₹7,910Cr vs ₹6,123Cr (▲29% YoY) EBITDA ₹1,923Cr vs ₹1,987Cr (▼3% YoY) PAT ₹926Cr vs ₹1,261Cr (▼27% YoY) EBITDA Margin 24.3% vs 32.5% (▼813bps)

Business Update Positive

2026-11-02 12:47

- Zydus Lifesciences Limited has successfully completed the acquisition of the API Business of Sterling Biotech Limited. - The acquisition was completed following the fulfillment of conditions precedent and closing date adjustments under the Business Transfer Agreement dated September 17, 2024.

Business Update Positive

2026-11-02 12:44

- Zydus Lifesciences Limited has successfully completed the acquisition of the API business of Sterling Biotech Limited. - The acquisition was completed following the fulfillment of all conditions precedent and closing date adjustments specified in the Business Transfer Agreement dated September 17, 2024.

Governance Neutral

2026-10-31 19:33

- Dr. Amrut Naik has resigned as President and Business Unit Head, International Markets Business, effective November 7, 2026. - Mr. Christoph Stoller has been appointed as the new President and Business Unit Head, International Markets Business, effective November 2, 2026. - Mr. Stoller brings over 30 years of global pharmaceutical industry experience, having previously held senior leadership roles at Glenmark Pharmaceuticals, Teva Pharmaceuticals, and Helvepharm AG.

Governance Neutral

2026-10-31 19:29

- Dr. Amrut Naik has resigned as President and Business Unit Head, International Markets Business, effective November 7, 2026. - Mr. Christoph Stoller has been appointed as the new President and Business Unit Head, International Markets Business, effective November 2, 2026.

Business Update Neutral

2026-10-24 11:37

Concall Schedule Concall Date: November 4, 2026 Concall Time: 3:30 PM IST

Business Update Neutral

2026-10-24 11:32

Concall Schedule Concall Date: November 4, 2026 Concall Time: 3:30 PM IST

Business Update Positive

2026-10-21 18:32

- Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale up Prolific's light-controlled cell line development platform to GMP manufacturing. - The collaboration aims to scale the technology from early development to 50-liter, 250-liter, and commercial GMP manufacturing at Zylidac's Emeryville facility. - The platform utilizes optogenetics to improve yield, product quality, and process control for complex biologics such as multi-specific antibodies and fusion proteins.

Business Update Positive

2026-10-21 18:29

Zylidac Bio, a subsidiary of Zydus Lifesciences, partnered with Prolific Machines to scale Prolific's light-controlled cell line development platform to GMP production. - The partnership integrates Prolific's optogenetics-enabled technology with Zylidac's manufacturing facility to scale biologics production from 50-liter trials to 250 liters and GMP manufacturing.

Business Update Positive

2026-10-21 11:13

- Zydus Lifesciences received final USFDA approval for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. - The product has been designated as a Competitive Generic Therapy (CGT) and is eligible for 180-day CGT exclusivity. - The drug had annual US sales of approximately USD 45.7 million as of August 2026.

Business Update Positive

2026-10-21 11:10

Zydus Lifesciences received final USFDA approval for Estradiol and Levonorgestrel Transdermal System. - The product is eligible for 180-day Competitive Generic Therapy (CGT) exclusivity. - The drug is used to treat moderate to severe symptoms of menopause and prevention of osteoporosis. - The product had annual US sales of approximately USD 45.7 million as of August 2026.

Governance Neutral

2026-10-19 12:19

- Board meeting scheduled on Wednesday, November 4, 2026, to consider and approve unaudited financial results for Q2/H1 ended September 30, 2026. - Trading window will remain closed until Friday, November 6, 2026, and reopen on Monday, November 9, 2026.

Business Update Positive

2026-10-16 17:01

- Zydus Lifesciences received an overall ESG rating of 71 for the financial year 2026 from NSE Sustainability Ratings and Analytics Limited (NSRAL). - The company has been placed under the 'leader' category. - The rating is unsolicited and was independently prepared by NSRAL using publicly available data.

Business Update Positive

2026-10-16 16:56

- Zydus Lifesciences has been assigned an overall ESG rating of 71 for the financial year 2026 by NSE Sustainability Ratings and Analytics Limited. - The rating places the company under the category of 'leader'. - The rating report was independently prepared by the agency based on publicly available data.

Business Update Positive

2026-10-15 11:33

- Zydus Sunshine Lifesciences signed an agreement with the Board of Investment of Sri Lanka to establish a pharmaceutical manufacturing facility in Horana, Sri Lanka. - The project involves a phased investment of over USD 20 million on a nearly four-acre site. - Commercial operations are expected to commence in 2028, focusing on oral solid dosage forms in the first phase.

Business Update Positive

2026-10-15 11:31

Business Update: Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka Order Value / Investment: Phased investment of over USD 20 million. Completion Timeline: Commercial operations expected to commence in 2028. Key Details: Establishment of a pharmaceutical manufacturing facility in Horana, Sri Lanka to manufacture oral solid dosage forms in its first phase.

Business Update Neutral

2026-10-13 20:35

- USFDA inspection concluded at Zydus Lifesciences' manufacturing plant located at Moraiya, Ahmedabad, conducted from 5th to 13th October 2026. - The inspection closed with 5 observations. - The company will closely work with the USFDA to address the observations expeditiously.

Business Update Neutral

2026-10-13 20:33

- USFDA inspection concluded at Zydus Lifesciences' manufacturing plant at Moraiya, Ahmedabad. - The inspection took place from 5th to 13th October 2026. - The inspection resulted in 5 observations. - The company will work closely with the USFDA to address the observations expeditiously.

Business Update Positive

2026-10-13 09:51

- USFDA has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), for review. - To the companies' knowledge, this is the first publicly announced acceptance by the USFDA of a filing for a Keytruda biosimilar. - Zydus holds exclusive commercialization rights for the US and Canada under a licensing and supply agreement with Formycon.

Business Update Positive

2026-10-13 09:47

Zydus Lifesciences and Formycon announced that the USFDA has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab). - This is reported to be the first publicly announced acceptance by the USFDA of a filing for a proposed Keytruda biosimilar. - Zydus holds exclusive commercialization rights for FYB206 in the United States and Canada. - A decision from the USFDA is expected in the third quarter of 2027 under the BsUFA timeline.

Business Update Positive

2026-10-12 18:05

Zydus Lifesciences presented a post hoc analysis of the Phase 3 EPICS-III trial at ACG 2026 for investigational saroglitazar in primary biliary cholangitis (PBC). - Results showed greater biochemical response with saroglitazar compared to placebo across geographic subgroups, with a numerically higher response in U.S. patients versus non-U.S. patients. - Saroglitazar is currently under review by the U.S. FDA, with a planned launch by March 2027 if approved.

Business Update Positive

2026-10-12 18:02

Zydus Lifesciences presented a new post hoc analysis of the Phase 3 EPICS-III trial for investigational saroglitazar at ACG 2026. - The analysis showed greater biochemical response with saroglitazar compared to placebo across geographic subgroups in patients with primary biliary cholangitis (PBC). - A numerically higher biochemical response treatment difference was observed in the U.S. subgroup relative to the non-U.S. subgroup (∆ 60.7% vs. ∆ 41.6%). - Saroglitazar is currently under review by the U.S. FDA, with a planned launch in the United States by March 2027 if approved.

Business Update Positive

2026-10-05 20:45

Order Win: Zydus Lifesciences and MSN Laboratories launched the first generic version of Adempas (Riociguat Tablets) in the U.S. across all five strengths (0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg). Details: Adempas global sales reached approximately EUR 745 million (USD 850 million) in 2025 according to Bayer's Annual Report.

Business Update Positive

2026-10-05 20:43

Zydus Lifesciences, in partnership with MSN Laboratories, has launched the first generic version of Adempas (Riociguat Tablets) in the U.S. across all five strengths. - The product is approved by the USFDA for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). - Global sales of the branded drug (Adempas) were approximately EUR 745 million in 2025.

Business Update Neutral

2026-10-01 21:58

- Zydus Lifesciences Limited and Sunshine Healthcare Lanka Limited have mutually agreed to extend the closing date for completing the conditions precedent under their Share Subscription and Shareholders' Agreement. - The joint venture entity, Zydus Sunshine Lifesciences (Private) Limited, will become a 50:50 joint venture upon completion. - The transaction is now expected to be completed by December 2026.

Business Update Neutral

2026-10-01 21:56

- Zydus Lifesciences and Sunshine Healthcare Lanka have mutually agreed to extend the closing date for completing the condition precedents of their 50:50 joint venture, Zydus Sunshine Lifesciences. - The transaction completion timeline is now extended to December 2026.

Business Update Neutral

2026-09-28 18:11

- USFDA conducted a cGMP inspection at Zydus' manufacturing plant at SEZ II, Ahmedabad from September 21 to 28, 2026. - The inspection concluded with a single observation and no data integrity related observations. - The company will work closely with the USFDA to address the observation expeditiously.

Business Update Neutral

2026-09-28 18:07

- USFDA conducted a cGMP inspection at Zydus' manufacturing plant at SEZ II, Ahmedabad from September 21 to 28, 2026. - The inspection concluded with one observation. - There were no data integrity related observations. - The company will work closely with the USFDA to address the observation expeditiously.

Routine Neutral

2026-09-26 13:50

- Trading window will remain closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter/half-year ending September 30, 2026. - Applies to Directors, Designated Persons, and their immediate relatives. - Board meeting date for approving results will be intimated later.

Routine Neutral

2026-09-26 13:42

- Trading window will remain closed from Thursday, October 1, 2026. - Closure applies until 48 hours after the declaration of unaudited financial results for the quarter/half year ending September 30, 2026. - Board meeting date for approving results will be intimated in due course.

Business Update Positive

2026-09-26 12:28

- USFDA inspection of pharmacovigilance and post marketing surveillance system concluded at Zydus' USA Office in New Jersey. - The inspection took place from September 22nd to September 25th, 2026. - The inspection successfully closed with NIL observations.

Business Update Positive

2026-09-26 12:25

- USFDA conducted an onsite inspection of pharmacovigilance and post marketing surveillance system at Zydus USA Office in New Jersey from September 22 to September 25, 2026. - The inspection successfully concluded with nil observations.

Business Update Positive

2026-09-11 14:36

- CRISIL Ratings reaffirmed credit ratings for Zydus Lifesciences Limited's various instruments on September 10, 2026. - Bank facilities (₹4,724 Cr) rated CRISIL AAA/Stable (long-term) and CRISIL A1+ (short-term). - Commercial Papers (₹200 Cr) rated CRISIL A1+. - Non-Convertible Debentures (₹125 Cr combined) rated CRISIL AAA/Stable. - Ratings indicate a very strong degree of safety and lowest credit risk.

Business Update Positive

2026-09-11 14:33

- Zydus Lifesciences Limited's credit ratings were reaffirmed by CRISIL Ratings on September 10, 2026. - Long-term ratings for bank facilities (₹4,724 Cr) and Non-Convertible Debentures (₹125 Cr) were reaffirmed at CRISIL AAA/Stable. - Short-term ratings for bank facilities and commercial papers (₹200 Cr) were reaffirmed at CRISIL A1+.

Business Update Neutral

2026-09-11 11:47

- Investor Conference - Company: Zydus Lifesciences Limited - Event: J.P. Morgan India Conference, 2026 - Date: September 21, 2026

Business Update Neutral

2026-09-11 11:43

- Investor Conference Schedule - Conference Name: J.P. Morgan India Conference - Conference Date: September 21, 2026

Business Update Positive

2026-09-01 11:00

- FY26 Consolidated Revenues reached ₹271.5 billion, representing 17% growth YoY. - FY26 EBITDA Margin was 31.2%. - FY27 guidance is for high-teen revenue growth, driven by Indian and international businesses, new product launches, and acquisitions. - Board approved a share buyback of up to ₹1,100 crore at ₹1,260 per share. - Saroglitazar Magnesium for Primary Biliary Cholangitis received US FDA Priority Review; US launch planned for Q4 FY27. - Tishtha® (nivolumab biosimilar) reached over 25,000 cancer patients in India. - Re. 1/- dividend (100%) declared for FY2025-26. - Mr. Kulin Lalbhai appointed as Independent Director for 5 years, and Dr. Sharvil Patel re-appointed as MD for 5 years.

Business Update Positive

2026-08-31 10:48

- Zydus Lifesciences announced positive topline results from its EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH. - The trial successfully met its primary endpoint of steatohepatitis resolution with no worsening of fibrosis. - This is a significant milestone for their MASH development program.

Business Update Positive

2026-08-31 10:45

- Zydus Lifesciences announced positive topline results from its EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH. - The trial met its primary endpoint: resolution of steatohepatitis with no worsening of fibrosis (26.5% treatment difference). - Also observed encouraging improvements in liver histology.

Business Update Positive

2026-08-26 11:16

- Zydus Lifesciences Limited incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, on August 25, 2026. - The 'Gift City Company' in Gandhinagar, Gujarat, will undertake global/regional corporate treasury activities and services. - The subsidiary is 100% owned with a paid-up share capital of Rs. 5 Crores.

Business Update Positive

2026-08-26 11:13

- Zydus Lifesciences Limited incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, on August 25, 2026. - The new entity, with ₹5 Cr paid-up capital, will serve as a Global/Regional Corporate Treasury Centre in Gift City, Gandhinagar.

Business Update Positive

2026-08-25 17:42

- CRISIL Ratings assigned Zydus Lifesciences an overall ESG Score of 66 for FY 2025-2026. - The previous score was 61, indicating an improvement. - CRISIL considers a score between 61-70 as 'strong'.

Business Update Positive

2026-08-25 17:05

- CRISIL Ratings assigned an overall ESG Score of 66 (previous: 61) to Zydus Lifesciences for FY 2025-2026. - A score between 61-70 is considered 'strong' as per CRISIL's rating framework.

Ownership Neutral

2026-08-24 19:42

- Mr. Prashant Babubhai Patel, Member of the Promoter Group, received 32,577 equity shares via transmission from Late Jasodaben Babubhai Patel, also a Member of the Promoter Group. The off-market transaction occurred on August 19, 2026.

Ownership Neutral

2026-08-24 19:38

- Zydus Lifesciences Limited disclosed the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel (Promoter Group Member) to Mr. Prashant Babubhai Patel (Promoter Group Member). - This disclosure was made under SEBI (Prohibition of Insider Trading) Regulations, 2015.

Business Update Positive

2026-08-23 12:40

- Zydus Lifesciences Ltd. filed an investor presentation for an upcoming investor conference scheduled from August 24-26, 2026. - The presentation highlights strong financial performance with double-digit CAGRs for Revenue, EBITDA, and PAT from FY21 to FY26. - It showcases market leadership in key segments, a robust innovation pipeline, and strategic growth drivers across geographies and therapeutic areas.

Business Update Positive

2026-08-23 12:35

- Zydus Lifesciences Ltd submitted its investor presentation for a conference on August 24-26, 2026. The presentation highlights strong financial performance with FY26 Revenue of INR 2,71,484 Mn, EBITDA of INR 84,751 Mn (31.2% margin), and PAT of INR 54,564 Mn (20.1% margin), reflecting consistent growth and a diversified global portfolio.

Business Update Neutral

2026-08-21 18:03

- Zydus Lifesciences Limited received an overall ESG rating of 60 from ESGRAIL, a SEBI registered ESG Rating Provider. - The company stated that it had not engaged ESGRAIL for this independent rating, which was based on publicly available information.

Business Update Neutral

2026-08-21 18:00

- Zydus Lifesciences Limited received an overall ESG rating of 60 from ESGRAIL, a SEBI registered ESG Rating Provider.- ESGRAIL independently prepared the report based on publicly available information, as the Company had not engaged them for this rating.

Business Update Positive

2026-08-21 13:57

- Zydus Lifesciences received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP. - The product has been designated as a Competitive Generic Therapy (CGT), granting 180-day exclusivity. - The brand product had annual sales of approximately USD 11.6 million in the United States as per IQVIA MAT June-2026. - The product will be manufactured at the company's USFDA-approved injectable plant in Jarod, Gujarat, and marketed in the US.

Business Update Positive

2026-08-21 13:54

- Zydus Lifesciences Limited received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP with 180-Days Competitive Generic Therapy (CGT) exclusivity. - The brand product had annual sales of approximately USD 11.6 million in the US.

Business Update Positive

2026-08-18 15:01

- Commenced FY27 with strong double-digit growth, registering consolidated revenues of ₹80.2 billion (▲22% YoY) and an EBITDA margin of 24.1%. Net profit for Q1 FY27 was ₹9.4 billion. - India branded formulations business grew 20% YoY, outpacing market; mid-teens growth expected for FY27. - International markets formulations business posted revenues of ₹9.7 billion (▲34% YoY); North America business revenues were ₹31 billion (▲5% QoQ). - Consumer Wellness business recorded revenues of ₹14.3 billion (▲67% YoY), with double-digit growth expected for FY27. - Maintained guidance for strong double-digit revenue growth and 24%+ EBITDA margin for FY27, with long-term target of 28-30% EBITDA margin within 5 years. - FY27 Capex is guided around ₹1,500-₹1,600 crores for facility expansion and R&D initiatives. - Key strategic initiatives include the launch of Nufymco™ (first US biosimilar), acquisition of Assertio Holdings, and progress on Saroglitazar Magnesium NDA (USFDA priority review, FY28 launch with $200-$400+ million potential). - Significant R&D pipeline advancements across biosimilars, vaccines, and NCEs, including Phase III trials for Desidustat (sickle cell disease) and a second ADC Biosimilar. - Planned 30-40 US product launches for FY27, with US branded business expected to contribute over 15% of US revenue by year-end.

Business Update Positive

2026-08-18 14:56

- FY27 revenue guidance of strong double-digit growth for the year. - India business is poised for mid-teens growth, outperforming the market by 300-500 basis points. - International markets and US business are expected to see around single-digit growth. - FY27 EBITDA margin guided at 24%+, with a medium-term target of 28-30% by FY30 as branded business scales. - FY27 Capex guidance is approximately ₹1,500-₹1,600 crores. - Saroglitazar (Saro) US launch expected in FY28, with the first 2 years being an investment phase and revenue buildup from the 2nd/3rd year. Target market potential of $200-$300 million, potentially crossing $400+ million. - Assertio acquisition is expected to add $15-$20 million per quarter run rate from the next quarter, with a large part allocated to intangibles. - Branded portfolio's share of total revenues is over 55% in Q1 FY27, anticipated to exceed two-thirds over the medium term. - Strong double-digit growth is expected for the Consumer Wellness and Comfort Click businesses in FY27. - 30-40 US launches, including specialty launches, are planned for FY27. - Desidustat has received approval in China and is considered a long-term opportunity with potential to contribute over $200 million in the Chinese market once reimbursement is in place. - Usnoflast (ALS) Phase 2(b) trial is ongoing, with data expected by end of FY28 or early FY29. - Mirabegron settlement continues to be a highly profitable driver for the business, despite higher associated costs impacting gross margins quarter-on-quarter. - Depreciation and amortization, elevated due to acquisitions and licensing amortizations, are expected to normalize after Q2 FY28.

Business Update Neutral

2026-08-17 16:13

- Zydus Lifesciences management will meet investors in Singapore and Hong Kong for a Non-Deal Roadshow (NDR). - The investor conference is scheduled from August 24 to August 26, 2026.

Business Update Neutral

2026-08-17 16:05

- Zydus Lifesciences Limited management to meet investors in Singapore and Hong Kong. - Meetings will be held from August 24, 2026, to August 26, 2026. - The format will be a Non-Deal Roadshow (NDR).

Business Update Neutral

2026-08-12 17:10

- Zydus Lifesciences Limited's participation in the Motilal Oswal 22nd Annual Global Investor Conference, 2026, has been rescheduled. - The conference will now be held on August 17, 2026, instead of August 18, 2026.

Business Update Neutral

2026-08-12 17:06

- Investor Conference Schedule Update - Zydus Lifesciences Limited's participation in the Motilal Oswal 22nd Annual Global Investor Conference, 2026, has been rescheduled. - The conference will now be held on August 17, 2026, instead of the previously intimated August 18, 2026.

Governance Positive

2026-08-11 20:37

- Zydus Lifesciences Limited announced voting results of its 31st Annual General Meeting held on August 11, 2026. - All resolutions were passed, including the adoption of financial statements, declaration of a final dividend of ₹1/- per equity share, and re-appointments of directors.

Governance Neutral

2026-08-11 20:32

- Re-appointment of Dr. Sharvil P. Patel as Managing Director for a further five years (April 1, 2027 to March 31, 2032). - Appointment of Mr. Kulin S. Lalbhai as an Independent Director for a term of five years (May 19, 2026 to May 18, 2031). - Both resolutions were passed at the 31st Annual General Meeting held on August 11, 2026.

Governance Neutral

2026-08-11 20:12

- Shareholders at the AGM on August 11, 2026, approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for five years (effective April 1, 2027). - Mr. Kulin S. Lalbhai was appointed as an Independent Director for five years (effective May 19, 2026).

Business Update Neutral

2026-08-11 19:57

- Zydus Lifesciences Limited announced the audio recording of the Investor Call discussing unaudited financial results for the quarter ended June 30, 2026, is available on the Company's website as of August 11, 2026.

Governance Negative

2026-08-11 19:08

CRITICAL RED FLAG DETECTED

- Zydus Lifesciences reported a violation of SEBI PIT Regulations by a Designated Person, Mr. Ashutosh Patil. - Mr. Patil engaged in an inadvertent contra trade of 171 equity shares valued at ₹3,36,166/-. - The company issued a warning letter and recovered the profit of ₹18,797/-, which was transferred to IEPF.

Business Update Positive

2026-08-11 18:53

- Zydus Lifesciences' subsidiary Sentynl Therapeutics entered an option and license agreement with Mereo BioPharma for alvelestat, a potential first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). - Sentynl gains exclusive U.S. commercial and global manufacturing rights. Mereo receives an upfront option fee, up to $40 million in payments, and double-digit tiered royalties.

Financials Negative

2026-08-11 13:31

- Q1 FY27 Consolidated Revenue ₹8,017Cr vs ₹6,573.7Cr (▲22.0% YoY) - EBITDA ₹1,929.4Cr vs ₹2,088.5Cr (▼7.6% YoY) - PAT ₹939.8Cr vs ₹1,466.8Cr (▼35.9% YoY) - EBITDA Margin 24.1% vs 31.8% (▼770bps)

Financials Negative

2026-08-11 13:28

- Q1 FY27 Consolidated Revenue ₹80,170 mn vs ₹65,737 mn (▲22% YoY) - EBITDA ₹19,294 mn vs ₹20,885 mn (▼7.6% YoY) - PAT ₹9,398 mn vs ₹14,668 mn (▼35.9% YoY) - EBITDA Margin 24.1% vs 31.8% (▼770 bps)

Financials Negative

2026-08-11 13:26

- Q1 FY27 Consolidated Revenue ₹80,170Mn vs ₹65,737Mn (▲22.0% YoY) - EBITDA ₹19,112Mn vs ₹20,885Mn (▼8.5% YoY) - PAT ₹9,398Mn vs ₹14,668Mn (▼35.9% YoY) - EBITDA Margin 23.8% vs 31.8% (▼793bps)

Business Update Positive

2026-08-10 15:22

- Zydus Lifesciences Limited launched REVAHALE™ (Revefenacin), India's first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) for Chronic Obstructive Pulmonary Disease (COPD). - REVAHALE™ offers sustained 24-hour bronchodilation through convenient nebulised delivery. - This therapy addresses challenges with inhaler-dependent treatments, particularly for elderly patients and those with severe respiratory impairment, by providing a nebulised delivery platform compatible with standard jet nebulisers.

Routine Neutral

2026-08-10 09:46

New Filing detected. See link for details.

Business Update Positive

2026-08-04 15:11

- Zydus Lifesciences received final USFDA approval for Indocyanine Green for Injection, USP, 25 mg/vial. - The approval includes 180-Days Competitive Generic Therapy (CGT) exclusivity. - The company plans to launch the product shortly in the US market. - The brand product had annual sales of approximately USD 125.8 million.

Business Update Neutral

2026-08-04 13:12

- Investor Conference Schedule - Conference Date: August 13, 2026 - Company will participate in the Emkay Confluence 2026 investor conference.

Routine Neutral

2026-08-04 13:04

New Filing detected. See link for details.

Business Update Positive

2026-08-01 14:44

- Zydus Lifesciences received an Establishment Inspection Report (EIR) from the USFDA. - The EIR is for its injectable facility in Ahmedabad. - The facility received a "Voluntary Action Indicated" (VAI) classification, following an inspection from April 27 to May 5, 2026.

Business Update Neutral

2026-07-30 17:21

- Concall Schedule - Concall Date: August 11, 2026 - Concall Time: 04:00 PM IST

Business Update Negative

2026-07-29 12:28

CRITICAL RED FLAG DETECTED

- Zydus Lifesciences received an order demanding ₹108.54 million for alleged deficient stamp duty and penalties on assets acquired from Sterling Biotech Limited. - The company is evaluating legal remedies.

Business Update Neutral

2026-07-25 16:09

- Zydus Lifesciences temporarily suspended some operations at its Ahmedabad facilities due to torrential rain and water logging. - Operations have started to resume as weather conditions improved.

Business Update Positive

2026-07-23 10:05

- Zydus Lifesciences received approval for Phase III clinical trial of Desidustat for patients with Sickle Cell Disease, in collaboration with ICMR. - The 203-day study will enroll 164 patients to evaluate efficacy and safety. - Desidustat also has US FDA Orphan Drug Designation for Sickle Cell Disease and beta-thalassemia.

Routine Neutral

2026-07-14 20:32

New Filing detected. See link for details.

Governance Positive

2026-07-10 13:39

- Annual General Meeting (AGM) for FY2025-26 to be held on August 11, 2026, at 10:00 a.m. (IST) via Video Conference/Other Audio Visual Means. - Dividend Payment Date is on or around August 14, 2026. - The Integrated Annual Report for the Financial Year ended March 31, 2026, has been submitted.

Business Update Positive

2026-07-03 12:22

- Zydus Lifesciences signed a Memorandum of Understanding (MoU) with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection (MCD) test in India. - The Shield MCD test, developed with Guardant Health, is a methylation-based blood test for early detection of 10 common cancer types in individuals aged 45 or older. - This collaboration aims to enhance timely cancer screening and improve patient outcomes through early diagnosis.

Business Update Neutral

2026-06-29 14:33

- Zydus Lifesciences extended the acquisition closing date for Sterling Biotech Limited's API business to September 30, 2026. - This is the second extension; the transaction was initially expected by Dec 31, 2024.

ZYDUSLIFE

Zydus Lifesciences Limited

Price Chart

Filing History

Unlock Full History